EU Approves Pfizer-BioNTech COVID-19 Vaccine for Adolescents

BioNTech SE (BNTX) and its partner Pfizer (PFE) have received Conditional Marketing Authorization (CMA) in the E.U. for their COVID-19 vaccine, COMIRNATY, for use in adolescents. BioNTech stock jumped 3.19% on Friday to close at $204.
The companies collaborated to develop COMIRNATY, which became the first vaccine against coronavirus to be approved in the EU. The initial approval was for use in adults. The latest approval expands the access of the COMIRNATY vaccine to adolescents 12 15 years of…

Click here to view the original article.